BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-pcac-503a-peptide-bulks-july-2026@catalyst-calendar.local
DTSTAMP:20260720T200627Z
DTSTART:20260723T123000Z
DTEND:20260723T130000Z
SUMMARY:FDA药房复方咨询委员会审议503A肽类等bulk substances窗口
DESCRIPTION:FDA药房复方咨询委员会将于2026年7月23日至24日讨论BPC-157、KPV、TB-500、MOTs-C、Semax、Epitalon等bulk substances是否纳入503A Bulks List，可能影响美国复方药房、肽类产品和部分代谢/抗衰老相关灰色市场监管预期。\\nImpact score: 58\\nExpected: 委员会讨论和投票将形成对相关复方bulk substances的监管信号；市场关注FDA对肽类复方、未批准用途和消费者健康市场的执法方向。\\nAffected: XBI(theme\, unknown\, score 32)\; HIMS(theme\, mixed\, score 45)\; LLY(theme\, mixed\, score 36)\; NVO(theme\, mixed\, score 36)\\nSources: FDA Advisory Committee Calendar: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026\\nFederal Register public inspection PDF: https://public-inspection.federalregister.gov/2026-07361.pdf\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-pcac-503a-peptide-bulks-july-2026
CATEGORIES:policy\,MACRO\,FDA\,compounding\,503A\,peptides\,regulatory
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA药房复方咨询委员会审议503A肽类等bulk substances窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA药房复方咨询委员会审议503A肽类等bulk substances窗口
END:VALARM
END:VEVENT
END:VCALENDAR